Repligen | RGEN - 销售和管理费用

金融业

USD

USD 2.95B

现金及等价物

USD 566.02M

USD 94.08M

USD 1.14B

USD 135.83M

USD 542.21M

USD 19.97M

USD 39.54M

1.78K

EPS每股收益

USD 0.49

股本和储备

USD 2.11B

USD 103.83M

债务利息支出

USD 5.5M

USD 7.31M

USD 542.21M

USD 6.22B

USD 13.29M

USD 177.95M

USD 19.97M

普通股股本

USD 56.33M

164.06

USD 17.11M

USD 197.91M

销售和管理费用

USD 74.36M

USD 170.46M

贸易债权人

USD 30.01M

应收帐款人

USD 158.59M

	销售和管理费用	更改		日
Agilent	USD 476M		48M	2025-12
Align Technology	USD 441.68M		23.88M	2025-12
Bio Techne	USD 113.69M		2.52M	2025-12
BioMarin Pharmaceutical	USD 322.21M		98.79M	2025-12
Bristol-Myers Squibb	USD 2.18B		392M	2025-12
Bruker	USD 247.2M		4.7M	2025-12
Charles River Laboratories	USD 196.14M		18.55M	2025-12
Danaher	USD 2.03B		35M	2025-12
Dentsply International	USD 383M		28M	2025-12
General Electric Aerospace	USD 1.58B		385M	2025-12
Henry Schein	USD 808M		48M	2025-12
Illumina	USD 283M		27M	2025-12
IQVIA Holdings	USD 468M		46M	2025-12
Mettler Toledo International	USD 259.83M		11.43M	2025-12
Myriad Genetics	USD 122.3M		6.7M	2025-12
OraSure Technologies	USD 13.21M		3.29M	2025-12
Pacific Biosciences Of California	USD 37.24M		25.68M	2025-12
Pfizer	USD 4.08B		894M	2025-12
Repligen	USD 74.36M		703K	2025-12
Revvity	USD 251.73M		9.82M	2025-12
Standard Biotools	USD 21.55M		5.05M	2025-12
Thermo Fisher Scientific	USD 1.98B		182M	2025-12
Waters	USD 240.01M		25.78M	2025-12
West Pharmaceutical Services	USD 106.5M		3.8M	2025-12